This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street

Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks to buy according to Wall Street analysts. On November 20, H.C. Wainwright reaffirmed its Buy rating and $102 price target on Viking Therapeutics, Inc. (NASDAQ:VKTX) after the company finished enrollment ahead of schedule in its Phase 3 VANQUISH-1 obesity study, bringing in 4,650 adults instead of the planned 4,500. The trial includes people with obesity or overweight and related health conditions, marking an important step forward for Viking’s pipeline.

The VANQUISH 2 study, which is enrolling 1,100 adults with type 2 diabetes who are also obese or overweight, is expected to complete enrollment in early 2026. Both trials are evaluating weekly injections of VK2735 at several dose levels compared with placebo, with the primary goal being percent weight change at week 78. Additional measures include weight-loss milestones and safety results, and participants receiving VK2735 can continue treatment in an open-label extension.

At the Jefferies London Healthcare Conference 2025 on November 19, Viking Therapeutics reiterated that it is making significant progress in developing its pipeline, including VK2735, an obesity treatment. The company is advancing the obesity candidate drug into Phase III trials for a subcutaneous formulation, following topline Phase II results showing up to 12.2% weight loss.

The company’s Amylin agonist program is advancing into clinical trials, with plans to file an IND next year. The company exited the third quarter with $700 million in cash reserves sufficient to accelerate the pipeline development.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine diseases like obesity, fatty liver (MASH/NAFLD), and rare conditions like X-ALD, primarily using small-molecule drugs that target hormone receptors (like GLP-1/GIP, TRβ agonists) for weight loss, cholesterol, and liver fat reduction.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.